In vitro activity of contezolid against gram-positive bacteria isolated from pediatric patients with invasive infections
Microbiology Spectrum · 03.11.2026 · 14 (11)
DOI: 10.1128/spectrum.02949-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbiology Spectrum, erschienen am 03.11.2026. Verfasst von Xinrong Li und 3 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Intensive Care Unit, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Gram-Positive Bacteria, Oxazolidinones, Gram-Positive Bacterial Infections. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Beijing Municipal Science and Technology Commission, Adminitrative Commission of Zhongguancun Science Park.
Abstract (Originalsprache)
Contezolid, a novel oxazolidinone, exhibits potent activity against multidrug-resistant gram-positive pathogens, but data in pediatric populations remain limited. This study evaluated the in vitro activity of contezolid against Streptococcus pneumoniae ( n = 53) and Staphylococcus aureus ( n = 92) isolates recovered from sterile-site specimens of pediatric patients with invasive infections (2018–2023). MICs were determined by broth microdilution. For S. pneumoniae , contezolid MICs ranged from 0.125 to 1.000 µg/mL (MIC 50/90 , 0.250/0.500 µg/mL), with comparable activity against penicillin-susceptible and penicillin-nonsusceptible isolates. Contezolid exhibited low MIC values with a relatively narrow distribution across serotypes and specimen sources, without marked differences. For S. aureus , contezolid MICs ranged from 0.250 to 2.000 µg/mL (MIC 50/90 , 0.500/1.000 µg/mL), with equivalent activity against methicillin-susceptible Staphylococcus aureu s (MSSA) and methicillin-resistant Staphylococcus aureus (MRSA). All isolates were susceptible, with most MICs ≤ 0.500 µg/mL and a minority ( n = 25) at 1–2 µg/mL, mostly involving isolates from blood. Contezolid exhibited potent and consistent in vitro activity against gram-positive pathogens isolated from invasive infections in pediatric patients, including MRSA and PNSP, with stable susceptibility profiles across major clonal lineages. These findings demonstrate favorable in vitro activity of contezolid against clinically significant isolates. IMPORTANCE This study provides an evaluation of the in vitro activity of contezolid against gram-positive bacterial isolates obtained exclusively from pediatric patients with invasive infections. By characterizing susceptibility patterns across resistance phenotypes and molecular backgrounds, our findings offer important baseline data to inform future clinical studies of contezolid in pediatric populations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pediatric Intensive Care Unit, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
ORCID-Profile: Xinrong Li, Suyun Qian
Förderung
- Beijing Municipal Science and Technology Commission, Adminitrative Commission of Zhongguancun Science Park
Zitieren
APA
Li, X., Li, R., Qian, S., & Wang, Q. (2026). In vitro activity of contezolid against gram-positive bacteria isolated from pediatric patients with invasive infections. Microbiology Spectrum, 14(11). https://doi.org/10.1128/spectrum.02949-25
Vancouver
Li X, Li R, Qian S, Wang Q. In vitro activity of contezolid against gram-positive bacteria isolated from pediatric patients with invasive infections. Microbiology Spectrum. 2026;14(11). doi:10.1128/spectrum.02949-25
BibTeX
@article{Li2026,
author = {Li, Xinrong and Li, Rubo and Qian, Suyun and Wang, Quan},
title = {In vitro activity of contezolid against gram-positive bacteria isolated from pediatric patients with invasive infections},
journal = {Microbiology Spectrum},
year = {2026},
volume = {14},
number = {11},
doi = {10.1128/spectrum.02949-25}
}
EUVIMED